CLDN18 and carcinoma: We used the immunohistochemical study antibody (Ventana, clone 43–14 A) and, in accordance with the study specifications, uniformly evaluated a carcinoma as positive if at least 75% of the tumor cells showed membranous expression of CLDN18.2 with intensity score 2 or score 312.